Clinical Trial Update: Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety and tolerability of GW786034 in combination with lapatinib in cancer patients, including those with renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• GW786034
• Lapatinib (Lapatinib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Carcinoma, Renal Cell | Phase 1 | Status: COMPLETED